Ni F, Tan X, Zhang J, Guo T, Yuan Z, Wang X
Clin Exp Med. 2025; 25(1):61.
PMID: 39961952
PMC: 11832626.
DOI: 10.1007/s10238-025-01592-4.
Pham D, Hsu T
J Biomed Sci. 2025; 32(1):17.
PMID: 39920694
PMC: 11806631.
DOI: 10.1186/s12929-024-01111-9.
Chu M, Zhang Z, Wang Z, Li Z, Guo Y
Medicine (Baltimore). 2025; 104(5):e41375.
PMID: 39889162
PMC: 11789870.
DOI: 10.1097/MD.0000000000041375.
Lyu F, Zhong Y, He Q, Xiao W, Zhang X
BMC Cancer. 2025; 25(1):148.
PMID: 39871215
PMC: 11771106.
DOI: 10.1186/s12885-025-13534-0.
Ahmadi M, Motallebinezhad M, Mousavi P, Miladipour A, Fooladgar S, Ghafouri-Fard S
Discov Oncol. 2025; 16(1):28.
PMID: 39789365
PMC: 11717778.
DOI: 10.1007/s12672-025-01780-4.
Expression pattern of cancer-associated cellular senescence genes in clear cell renal cell carcinoma distinguishes tumor subclasses with clinical implications.
Zhu Z, Cao Q, Chen J, Sun Y, Liu F, Li J
Sci Rep. 2025; 15(1):442.
PMID: 39747640
PMC: 11695857.
DOI: 10.1038/s41598-024-84620-9.
Integrated machine learning reveals the role of tryptophan metabolism in clear cell renal cell carcinoma and its association with patient prognosis.
Li F, Hu H, Li L, Ding L, Lu Z, Mao X
Biol Direct. 2024; 19(1):132.
PMID: 39707545
PMC: 11662763.
DOI: 10.1186/s13062-024-00576-w.
PSENEN influences the progression of renal clear cell carcinoma by regulating the immune microenvironment and oxidative phosphorylation.
Huang C, Chen K, Zhu S, Yang X, Hou J, Gu X
PeerJ. 2024; 12:e18457.
PMID: 39624136
PMC: 11610461.
DOI: 10.7717/peerj.18457.
FXR promotes clear cell renal cell carcinoma carcinogenesis via MMP-7-regulated EMT pathway.
Liu J, Huang S, Hou Y, Fu S, Wang L, Hu J
Sci Rep. 2024; 14(1):29411.
PMID: 39592748
PMC: 11599922.
DOI: 10.1038/s41598-024-80368-4.
Exploring the Immune Landscape of ccRCC: Prognostic Signatures and Therapeutic Implications.
Pan M, Xu X, Zhang D, Cao W
J Cell Mol Med. 2024; 28(22):e70212.
PMID: 39557632
PMC: 11573483.
DOI: 10.1111/jcmm.70212.
Developing hypoxia and lactate metabolism-related molecular subtypes and prognostic signature for clear cell renal cell carcinoma through integrating machine learning.
Liu J, Yang T, Liu J, Hao X, Guo Y, Luo S
Discov Oncol. 2024; 15(1):653.
PMID: 39538070
PMC: 11561225.
DOI: 10.1007/s12672-024-01543-7.
Cuproptosis-related signature predicts prognosis and indicates tumor immune infiltration in bladder cancer.
Sheng H, Gu J, Huang Y, Kolat D, Shi G, Yan L
Transl Androl Urol. 2024; 13(10):2280-2293.
PMID: 39507864
PMC: 11535731.
DOI: 10.21037/tau-24-456.
ATF4/NUPR1 axis promotes cancer cell survival and mediates immunosuppression in clear cell renal cell carcinoma.
Lu Y, Chen W, Xuan Y, Li X, Wu S, Wang H
Discov Oncol. 2024; 15(1):607.
PMID: 39480570
PMC: 11528094.
DOI: 10.1007/s12672-024-01485-0.
Detection and Validation of Organic Metabolites in Urine for Clear Cell Renal Cell Carcinoma Diagnosis.
Holbrook K, Quaye G, Noriega Landa E, Su X, Gao Q, Williams H
Metabolites. 2024; 14(10).
PMID: 39452927
PMC: 11509871.
DOI: 10.3390/metabo14100546.
Screening of differential gene expression patterns through survival analysis for diagnosis, prognosis and therapies of clear cell renal cell carcinoma.
Ajadee A, Mahmud S, Hossain M, Ahmmed R, Ali M, Reza M
PLoS One. 2024; 19(9):e0310843.
PMID: 39348357
PMC: 11441673.
DOI: 10.1371/journal.pone.0310843.
Identification of a novel PANoptosis-related gene signature for predicting the prognosis in clear cell renal cell carcinoma.
Yue D, Ren C, Li H, Liu X
Medicine (Baltimore). 2024; 103(39):e39874.
PMID: 39331898
PMC: 11441883.
DOI: 10.1097/MD.0000000000039874.
Adjuvant therapy in renal cell carcinoma: Tyrosine kinase inhibitor versus immune checkpoint inhibitor.
Zhou Q, Liu J, Xie S
Medicine (Baltimore). 2024; 103(22):e38329.
PMID: 39259118
PMC: 11142775.
DOI: 10.1097/MD.0000000000038329.
Integrated Germline and Somatic Features Reveal Divergent Immune Pathways Driving Response to Immune Checkpoint Blockade.
Sears T, Pagadala M, Castro A, Lee K, Kong J, Tanaka K
Cancer Immunol Res. 2024; 12(12):1780-1795.
PMID: 39255339
PMC: 11612627.
DOI: 10.1158/2326-6066.CIR-24-0164.
Identification and Validation of Cytotoxicity-Related Features to Predict Prognostic and Immunotherapy Response in Patients with Clear Cell Renal Cell Carcinoma.
Yu J, Zhao B, Yu Y
Genet Res (Camb). 2024; 2024:3468209.
PMID: 39247556
PMC: 11379509.
DOI: 10.1155/2024/3468209.
Decreased PANK1 expression in kidney renal clear cell carcinoma: impact on cell apoptosis, invasion, migration, and epithelial-mesenchymal transition.
Liu X, Gao S, Qin Y, Zhang W, Li P, Xiang X
Discov Oncol. 2024; 15(1):380.
PMID: 39196459
PMC: 11358577.
DOI: 10.1007/s12672-024-01251-2.